An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
Asís Palazón(Ikerbasque), Randall S. Johnson(Athena Group (United States)), Thomas Hatschek(Karolinska University Hospital), Ingrid Hedenfalk(Lund University), Pedro Veliça(Karolinska Institutet), John Lövrot(Karolinska University Hospital), Nikola Vojnović(Karolinska Institutet), Ananda W. Goldrath(University of California San Diego), David Macías(Cancer Research UK Cambridge Center), Theodoros Foukakis(Karolinska Institutet), Anthony T. Phan(California University of Pennsylvania), Jonas Bergh(Karolinska Institutet), Susan F. Fitzpatrick(Cancer Research UK Cambridge Center), Helene Rundqvist(Karolinska University Hospital), Niklas Loman(Lund University), Petros A. Tyrakis(Cancer Research UK)
Cited by 534
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k